Travatan eye drops 40mg ml 2.5ml
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Travoprost
Release form
Drops
Composition
Eye solution-drops 1 ml: Duasorb water-soluble polymer system containing: dextran 70 1 mg disodium edetate 500 μg sodium chloride 7.7 mg potassium chloride 1.2 mg benzalkonium chloride (in the form of a solution) 100 μg of hypromellose (hydroxypropylmethylcellulose) 3 mg Substances; and / or sodium hydroxide solution (to maintain the pH level), purified water.
Pharmacological effect
Antiglaucoma drug. Synthetic analogue of prostaglandin F2α. It is a highly selective agonist of prostaglandin FP receptors. Reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor. The intraocular pressure decreases approximately 2 hours after the drug is applied, the maximum effect is achieved after 12 hours.
Pharmacokinetics
Absorption and metabolism Travoprost is absorbed through the cornea of the eye, where hydrolysis of the travoprost to the biologically active form - travoprost occurs. Cmax of travoprost in plasma is reached within 30 minutes after topical administration and is 25 pg / ml or less. Withdrawal Travoprost is rapidly removed from the plasma; within an hour, the concentration decreases below the detection threshold (<10 pg / ml). Travoprost is excreted in the form of inactive metabolites mainly with bile (61%), the rest is excreted by the kidneys.
Indications
Reducing elevated intraocular pressure with: open-angle glaucoma; increased intraocular pressure.
Contraindications
children and adolescents up to 18 years; - hypersensitivity to the drug. Precautions should be prescribed the drug to patients with risk factors for the development of macular edema (aphakia, pseudophakia, damage to the posterior lens capsule), with acute iritis, uveitis.
Precautionary measures
Use in children The drug is contraindicated in children and adolescents under 18 years of age.
Use during pregnancy and lactation
The purpose of the drug during pregnancy is contraindicated. Sufficient experience of the drug during lactation is not. Application during breastfeeding is possible only under the supervision of a physician and only in the case when the expected therapeutic effect for the mother exceeds the risk of possible side effects for the child.
Dosage and administration
The drug is instilled in 1 drop in the conjunctival sac of the affected eye (s) 1 time per day, preferably in the evening. More frequent use of the drug can lead to a decrease in its effectiveness.
Side effects
On the part of the organ of vision: in 35% of cases - transient mild hyperemia of the conjunctiva, passing independently; in 5-10% of cases - a decrease in visual acuity, a feeling of discomfort and a foreign body, pain, itching, burning in the eyes; in 1-4% of cases - visual disorders, blepharitis, mist before eyes, cataract, conjunctivitis, dry conjunctiva, changes in the color of the iris, keratitis, formation of crusts at the edges of the eyelids, photophobia, subconjunctival hemorrhage and increased tearing. Since the cardiovascular system: in 1-5% of cases - increase or decrease in blood pressure, bradycardia, angina, chest pain, hypercholesterolemia. From the side of the central nervous system: in 1-5% of cases - general anxiety, headache, depression. On the part of the urinary system: in 1-5% of cases - urinary incontinence and urinary system infections. From the musculoskeletal system: in 1-5% of cases - arthritis, back pain. Other: in 1-5% of cases - flu-like syndrome, sinusitis, bronchitis, dyspepsia.
Overdose
Symptoms: irritation of the mucous membrane of the eye, conjunctival hyperemia or episclera. Treatment: conduct symptomatic therapy.
Interaction with other drugs
Interaction with other drugs is currently not established.
special instructions
The drug may cause a gradual change in eye color by increasing the amount of brown pigment in the iris. This effect is detected mainly in patients with mixed colors of the iris, for example, blue-brown, gray-brown, green-brown or yellow-brown, which is explained by an increase in the content of melanin in the stromal melanocytes of the iris. Usually brown pigmentation spreads concentrically around the pupil to the periphery of the iris of the eye, while the entire iris or its parts may acquire a more intense brown color. In patients with evenly colored blue, gray, green or brown eyes, changes in eye color after two years of use were very rare.A change in color is not accompanied by any clinical symptoms or pathological changes. After discontinuation of the drug, no further increase in the amount of brown pigment was observed, however, the color change that has already developed may be irreversible. Before treatment, patients should be informed about the possibility of changing the color of the eyes. Treatment of only one eye can lead to permanent heterochromia. In the presence of nevi or lentigo on the iris, their changes are not observed under the influence of the drug. The drug may cause darkening, thickening and lengthening of eyelashes and / or an increase in their number; rarely - darkening of the eyelid skin. Travatan can be used in combination with other antiglaucoma drugs for local use. In this case, the interval between their use should be at least 5 minutes. When wearing contact lenses before instillation of the drug, the lenses should be removed and installed back no earlier than 20 minutes after the procedure. The bottle must be closed after each use. Do not touch the eye with a pipette tip.